EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis

Kathryn J Potter, Jackie Phinney, Tasha Kulai, Vicki Munro iD

Journal of the Canadian Association of Gastroenterology · 11.04.2025 · 8 (2) · 47-57

DOI: 10.1093/jcag/gwae057 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the Canadian Association of Gastroenterology, online erschienen am 29.01.2025. Verfasst von Kathryn J Potter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 4Z5, Canada. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-alcoholic fatty liver disease (NAFLD) is common, can progress to cirrhosis and hepatic decompensation, and has no approved medical therapy in Canada.

Objective

We conducted a systematic review on whether glucagon-like peptide-1 receptor agonists (GLP-1RA) improve non-alcoholic steatohepatitis (NASH) compared to standard care in NAFLD.

Methods

We searched Medline Ovid, EMBASE(Elsevier), Cochrane CENTRAL, Clinical Trials.gov, and the World Health Organization International Clinical Trials Registry Platform in November 2023 for randomized controlled trials. Inclusion criteria included patients ≥13 years with NAFLD receiving GLP-1RA for ≥6 months compared to standard care/placebo. Cochrane risk-of-bias 2.0 tool was used for each outcome. After screening results in duplicate, we performed meta-analysis and reported odds ratios (OR) for dichotomous and mean difference of change score for continuous outcomes.

Results

Six studies with 478 patients met inclusion criteria; 3 studies reported on the primary endpoint resolution of NASH. GLP-1RA likely leads to resolution of NASH (OR 4.45 (95% CI 1.92, 10.3)) and reduction in liver steatosis on imaging (–5.09% (95% CI −7.49, −2.69), but little to no reduction in liver stiffness on imaging (mean difference –0.17 kPa (95% CI −0.34, 0)).

Interpretation

Treatment with GLP-1RA in NAFLD patients for ≥6 months can probably lead to improvement in NASH on liver biopsy and reduce liver steatosis on imaging. Whether improvements in steatosis on biopsy or imaging results in clinically significant outcomes need to be elucidated as the effects of GLP-1RA on liver fibrosis are unclear; larger ongoing trials may provide more definitive answers. Protocol Registration: PROSPERO–CRD42023472186.

Schlagwörter

Stichwörter der Autor:innen

GLP-1NAFLDSteatohepatitis

Autor:innen und Institutionen

  • Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 4Z5, Canada.
  • Dalhousie University, Dalhousie Medicine New Brunswick, Saint John, NB, E2L 4L5, Canada.
  • Division of Digestive Care and Endoscopy, Dalhousie University, Halifax, NS, B3H 2Y9, Canada.
  • Division of Endocrinology, Dalhousie University, Halifax, NS, B3H 2Y9, Canada.

ORCID-Profile: Vicki Munro

Zitieren

APA

Potter, K. J., Phinney, J., Kulai, T., & Munro, V. (2025). Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of the Canadian Association of Gastroenterology, 8(2), 47-57. https://doi.org/10.1093/jcag/gwae057

Vancouver

Potter KJ, Phinney J, Kulai T, Munro V. Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of the Canadian Association of Gastroenterology. 2025;8(2):47-57. doi:10.1093/jcag/gwae057

BibTeX
@article{Potter2025,
  author = {Potter, Kathryn J and Phinney, Jackie and Kulai, Tasha and Munro, Vicki},
  title = {Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis},
  journal = {Journal of the Canadian Association of Gastroenterology},
  year = {2025},
  volume = {8},
  number = {2},
  pages = {47--57},
  doi = {10.1093/jcag/gwae057}
}
Kostenlos starten →